Search

Your search keyword '"James R. Burke"' showing total 226 results

Search Constraints

Start Over You searched for: Author "James R. Burke" Remove constraint Author: "James R. Burke"
226 results on '"James R. Burke"'

Search Results

1. Prefrontal contributions to relational encoding in amnestic mild cognitive impairment

3. New insights into the genetic etiology of Alzheimer's disease and related dementias

4. Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time

5. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

6. Pharmacodynamics‐based approach for efficacious human dose projection of BMS‐986260, a small molecule transforming growth factor beta receptor 1 inhibitor

7. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2

8. Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design Approaches

9. Metabolic and Neurocognitive Changes Following Lifestyle Modification: Examination of Biomarkers from the ENLIGHTEN Randomized Clinical Trial

10. The Preventing Alzheimer's with Cognitive Training (PACT) randomized clinical trial

11. Association Between Insulin Resistance, Plasma Leptin, and Neurocognition in Vascular Cognitive Impairment

12. Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)

13. Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS

14. Retinal Microvascular and Neurodegenerative Changes in Alzheimer’s Disease and Mild Cognitive Impairment Compared with Control Participants

15. Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors

16. Effects of pioglitazone on mnemonic hippocampal function: A blood oxygen level–dependent functional magnetic resonance imaging study in elderly adults

17. Assessing the Retinal Microvasculature in Individuals With Early and Late-Onset Alzheimer's Disease

19. List of Contributors

21. Measurement Properties of the CAPACITY Instrument to Assess Perceived Communication With the Health Care Team Among Care Partners of Patients With Cognitive Impairment

22. Convolutional neural network to identify symptomatic Alzheimer's disease using multimodal retinal imaging

23. Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK

24. Association of OCT Angiography Parameters With Age in Cognitively Healthy Older Adults

25. How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment?

26. Lifestyle and neurocognition in older adults with cognitive impairments

27. Lifestyle and Neurocognition in Older Adults With Cardiovascular Risk Factors and Cognitive Impairment

28. Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling

29. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging

30. A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton's Tyrosine Kinase

31. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

32. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

33. Identification of

34. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)

35. Longer Term Effects of Diet and Exercise on Neurocognition: 1-Year Follow-up of the ENLIGHTEN Trial

36. Identification of Imidazo[1,2

37. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers

38. A genetics-based biomarker risk algorithm for predicting risk of Alzheimer's disease

40. AB0026 SELECTIVE INHIBITION OF TYROSINE KINASE 2 WITH AN ORAL AGENT, BMS-986165, COMPARED WITH JANUS KINASE INHIBITORS

41. 1084 INDEPENDENT VALIDATION OF AN ACCURATE METHYLATED DNA MARKER PANEL FOR THE NON-ENDOSCOPIC DETECTION OF BARRETT'S ESOPHAGUS : A MULTISITE CASE CONTROL STUDY

42. HOW WELL DO PATIENTS AND THEIR CARE PARTNERS UNDERSTAND RESULTS OF AMYLOID PET SCANS?

43. P1‐034: CULTURALLY DIVERSE PARTICIPANT REGISTRIES TO FACILITATE THE RECRUITMENT OF AFRICAN AMERICANS INTO PRECLINICAL ALZHEIMER'S DISEASE STUDIES

44. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series

45. Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs

46. P2-566: LONG-TERM PESTICIDE USE AND RISK OF DEMENTIA IN THE AGRICULTURAL HEALTH STUDY OF MEMORY IN AGING

47. DT-02-02: TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM

48. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)

49. Stability of Diagnoses of Cognitive Impairment, Not Dementia in a Veterans Affairs Primary Care Population

50. A Plan for Academic Biobank Solvency-Leveraging Resources and Applying Business Processes to Improve Sustainability

Catalog

Books, media, physical & digital resources